25 Nov

The University of Sheffield and Pfizer have launched a new consortium which aims to standardise and accelerate the development of Advanced Therapy Medicinal Products (ATMPs), allowing potentially transformative treatments to reach patients sooner.

Led by ARDAT Coordinator, Professor Mimoun Azzouz from the University of Sheffield, and ARDAT Project Lead, Dr Gregory LaRosa from Pfizer, the new consortium will pioneer a €25.5 million project to accelerate the development of ATMPs which includes gene and cell therapies. The field of ATMP research is expected to grow exponentially in the coming years, with potentially up to 10-20 new drug applications submitted per year to the US FDA by 2025.

The ARDAT consortium will aim to bring together researchers from public and private organizations to help fill the knowledge gaps in how these therapies could potentially work, and to develop appropriate standards to aid researchers, developers and regulators in accelerating effective and safe gene and cell therapies to benefit patients.

"While still an emerging field, ATMP research has largely been fragmented and siloed within organisations with little opportunity to share best practices and information. As gene and cell therapies research grows and more potential ATMPs move into later-stage clinical trials, it is in the interest of the industry and of patients to further our collective understanding of their mechanisms by sharing data and regulatory expertise," said Dr Greg LaRosa, Head of Scientific Research, Rare Disease Research Unit at Pfizer.

Source : Express Pharma

* The email will not be published on the website.